Strategic partnerships Potential for collaboration with universities and research institutes leveraging Neochromosome’s neoYeast platform and synthetic DNA capabilities to accelerate drug discovery and enzyme design, as evidenced by past engagement with the University of Edinburgh.

Strategic partnerships Opportunity to target biopharma companies seeking computational biology and non-canonical amino acid chemistries, aligning with Sumitovant’s DrugOME ecosystem to identify novel proteins and expand joint R&D programs.

Platform Upsell Cross-sell integrated services from de novo design and chromosome delivery to automated DNA synthesis, appealing to customers needing end-to-end genome-scale engineering for therapeutics and sustainable product development.

AI and automation Highlight Neochromosome’s use of AI-enabled design and automated workflows to reduce iteration cycles, offering a compelling value proposition for customers aiming to accelerate research timelines and reduce lab overhead.

Market positioning Position as a niche yet capable partner with first-in-class genome-scale capabilities to compete with mid-tier players, targeting firms seeking unique synthetic biology platforms that enable designer enzymes and non-natural chemistries.